Antibody-based treatment of acute myeloid leukaemia Journal Article
| Authors: | Mulford, D. A.; Jurcic, J. G. |
| Article Title: | Antibody-based treatment of acute myeloid leukaemia |
| Abstract: | Monoclonal antibodies have become an important treatment modality in cancer therapy. Genetically engineered chimaeric and humanised antibodies have demonstrated activity against a variety of tumours. Whereas the humanised anti-CD33 monoclonal antibody HuM195 has only modest activity against overt acute myeloid leukaemia (AML), it can eliminate minimal residual disease detectable by reverse transcription-polymerase chain reaction in acute promyelocytic leukaemia. High-dose radioimmunotherapy with β -particle-emitting isotopes targeting CD33, CD45 and CD66 can potentially allow intensification of antileukaemic therapy before bone marrow transplantation. Conversely, α-particle immunotherapy with isotopes such as bismuth-213 or actinium-225 offers the possibility of selective tumour cell kill while sparing surrounding normal cells. Targeted chemotherapy with the anti-CD33-calicheamicin construct gemtuzumab ozogamicin has produced remissions as a single agent in patients with relapsed AML and appears promising when used in combination with standard chemotherapy in the treatment of newly diagnosed AML. |
| Keywords: | unclassified drug; acute granulocytic leukemia; clinical trial; drug activity; review; cancer combination chemotherapy; drug safety; nonhuman; drug targeting; radiation dose; cytarabine; animals; interleukin 2; unindexed drug; reverse transcription polymerase chain reaction; liver toxicity; nephrotoxicity; bone marrow suppression; etoposide; antineoplastic combined chemotherapy protocols; monoclonal antibodies; monoclonal antibody; fever; cancer regression; antibodies, monoclonal; rigor; antigen; iodine 131; genetic engineering; leukemia, myeloid; mitoxantrone; promyelocytic leukemia; hyperbilirubinemia; radioisotope; radioimmunotherapy; bone marrow transplantation; cd45 antigen; acute disease; cd33 antigen; gemtuzumab ozogamicin; adult respiratory distress syndrome; tumor cell destruction; hum195; alpha radiation; chimeric antibody; lung edema; yttrium 90; actinium 225; astatine 211; bismuth 213; vein occlusion; monoclonal antibody m 195; monoclonal antibody m 195 bi 213; bismuth 212; rhenium 188; beta radiation; copper 67; gelonin; lead 212; humans; human; acute myeloid leukaemia; cd66 antigen; monoclonal antibody bc 8 i 131; monoclonal antibody bw 250 183 re 188; monoclonal antibody m 195 i 131; monoclonal antibody m 195 y 90; monoclonal antibody p67 i 131 |
| Journal Title: | Expert Opinion on Biological Therapy |
| Volume: | 4 |
| Issue: | 1 |
| ISSN: | 1471-2598 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2004-01-01 |
| Start Page: | 95 |
| End Page: | 105 |
| Language: | English |
| DOI: | 10.1517/14712598.4.1.95 |
| PROVIDER: | scopus |
| PUBMED: | 14680472 |
| DOI/URL: | |
| Notes: | Expert Opin. Biol. Ther. -- Cited By (since 1996):17 -- Export Date: 16 June 2014 -- CODEN: EOBTA -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work